



**FOR IMMEDIATE RELEASE**

February 9, 2022

**Part B Access for Seniors and Physicians (ASP) Coalition Expresses Concern for CMS' Proposed Coverage for Alzheimer's Disease Treatment**

The Part B Access for Seniors and Physicians (ASP) Coalition is watching with concern the Centers for Medicare & Medicaid Services (CMS) proposal to restrict Medicare beneficiary access to FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. The ASP Coalition is troubled by the precedent set by CMS' proposal to limit Medicare coverage to beneficiaries receiving a specified drug in a hospital outpatient setting and enrolled in an approved clinical trial. This approach could pose significant burdens for the 6 million Americans living with Alzheimer's disease today, many of whom are Medicare beneficiaries. For those who do not live near a facility meeting these requirements, or whose provider is not participating in an approved clinical trial, the CMS proposal creates a significant barrier to access. We are closely monitoring these developments and evaluating the impact of the CMS proposal on patients, providers, and the essential physician-patient partnership that is the foundation of high-quality health care.

For more information, please visit [www.PartBAccess.org](http://www.PartBAccess.org)